Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2019
SIETES contiene 92806 citas

 
 
 1 a 18 de 18 
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]
3.Tiene citas relacionadas Cita con resumen
Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017;377:1580-2. [Ref.ID 102100]
4.Tiene citas relacionadas Cita con resumen
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, ten Berg JM, Steg PG, Hohnloser SH, for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. [Ref.ID 102099]
5. Cita con resumen
Young K. Who might benefit from long-term DAPT? Risk score may help . Journal Watch 2015:1. [Ref.ID 99636]
6.Tiene citas relacionadas Cita con resumen
Dear JW, Antoine DJ, Park BK. Where are we now with paracetamol?. BMJ 2015;351:h3705. [Ref.ID 99251]
7. Cita con resumen
Lip GYH, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-94. [Ref.ID 98892]
8.Tiene citas relacionadas Cita con resumen
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Omiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon Di, Iancu AC, Trebacz J, Mauri L, for the Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents. The dual antiplatelet therapy randomized clinical trial. JAMA 2015;313:1113-21. [Ref.ID 98862]
9. Cita con resumen
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet J-P, Jacq L, Bernasconi F, Montalescot G, for the ACTION Study Group. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ 2014;349:g6269. [Ref.ID 98292]
10. Cita con resumen
Viles-Gonzalez JF, Halperin JL. Efficacy and safety of amiodarone in patients with atrial fibrillation in the era of target-specific anticoagulants. J Am Coll Cardiol 2014;64:1551-3. [Ref.ID 98230]
11. Cita con resumen
Anónimo. Pazopanib: épanchements péricardiques. Prescrire 2014;34:511. [Ref.ID 98072]
12. Cita con resumen
Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA 2014;311:353-4. [Ref.ID 97046]
13.Tiene citas relacionadas Cita con resumen
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Ioakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22. [Ref.ID 96586]
14.Tiene citas relacionadas Cita con resumen
May AE. Antiplatelet therapy after coronary stenting: for how long?. Lancet 2013;382:1684-5. [Ref.ID 96584]
15.Tiene citas relacionadas
Doroshow JH. Overcoming resistance to targeted anticancer drugs. N Engl J Med 2013;369:1852-3. [Ref.ID 96519]
16.Tiene citas relacionadas
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Godlman JM, Shah NP, Kantarjian H, PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96. [Ref.ID 96515]
17.Tiene citas relacionadas Cita con resumen
Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cadiovascular surveillance. N Engl J Med 2013;369:1779-81. [Ref.ID 96514]
18. Cita con resumen
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC, IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67. [Ref.ID 96410]
Seleccionar todas
 
 1 a 18 de 18